US Patent

US10201517 — Brimonidine gel compositions and methods of use

Formulation · Assigned to Galderma Laboratories LP · Expires 2031-06-13 · 5y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects improved topical gel compositions containing brimonidine, carbomer, and methylparaben for treating skin disorders.

USPTO Abstract

Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.

Drugs covered by this patent

Alphagan (BRIMONIDINE TARTRATE) · Senju Pharmaceutical Co., Ltd

Patent Metadata

Patent number: US10201517
Jurisdiction: US
Classification: Formulation
Expires: 2031-06-13
Drug substance claim: No
Drug product claim: Yes
Assignee: Galderma Laboratories LP
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.